Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice-Reference-Cited by-同舟云学术

Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice

Published:2015-01-31 Issue:8 Volume:6 Page:6136-6150
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Wu Min¹,Kim Sahn-Ho¹,Datta Indrani²,Levin Albert²,Dyson Gregory³,Li Jing⁴,Kaypee Stephanie⁵,Swamy M. Mahadeva⁵,Gupta Nilesh⁶,Kwon Ho Jeong⁷,Menon Mani¹,Kundu Tapas K.⁵,Reddy G. Prem-Veer¹

Affiliation:

1. Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA

2. Bioinformatics Core, Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA

3. Biostatistics Core, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA

4. Pharmacology Core, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA

5. Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, JNCASR, Bangalore, Karnataka, India

6. Department of Pathology, Henry Ford Hospital, Detroit, MI, USA

7. Department of Biotechnology, Translational Research Center for Protein Function Control, Yonsei University, Seoul, Republic of Korea

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. KAT’s in the Cradle: p300/CBP and Regulation of HIF-1 and Blood Pressure during Intermittent Hypoxia;American Journal of Respiratory Cell and Molecular Biology;2024-02

2. Effects of curcumin and ursolic acid in prostate cancer: A systematic review;Urologia Journal;2023-09-30

3. Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC;European Journal of Medicinal Chemistry;2023-02

4. Integrated Network Analysis to Determine CNN1, MYL9, TAGLN, and SORBS1 as Potential Key Genes Associated with Prostate Cancer;Clinical Laboratory;2023

5. Emerging epigenetic therapies—lysine acetyltransferase inhibitors;Epigenetic Cancer Therapy;2023